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ABSTRACT
Objectives: The purpose of present paper is to critically address the recent advances on diagnostic procedures of Sjögren’s 
syndrome, taking into account the attained local and systemic features of the disease.
Material and Methods: A comprehensive review of the available literature regarding to the diagnostic approaches to Sjögren’s 
syndrome was conducted. Eligible studies were identified by searching the electronic literature PubMed, Medline, Embase, 
and ScienceDirect databases for relevant reports (last search update January 2012) combining the MESH heading term 
“Sjögren’s syndrome”, with the words “diagnosis, diagnostic procedures, salivary gland function, ocular tests, histopathology, 
salivary gland imaging, serology”. The authors checked the references of the selected articles to identify additional eligible 
publications and contacted the authors, if necessary.
Results: Presented article addresses the established diagnostic criteria for Sjögren’s syndrome and critically evaluates the 
most commonly used diagnostic procedures, presenting data from author’s own clinical experience. Diagnostic criteria for 
Sjögren’s syndrome are required both by healthcare professionals and patients, namely in order to provide a rational basis for 
the assessment of the symptoms, establish an individual disease prognosis, and orientate the therapeutic intervention.
Conclusions: Sjögren’s syndrome is quite a common autoimmune disease of which the diagnosis and treatment are not easily 
established. Due to its systemic involvement, it can exhibit a wide range of clinical manifestations that contribute to confusion 
and delay in diagnosis. The use of proper diagnostic modalities will help to reduce the time to diagnosis and preserve the 
health and quality of life of patients with Sjögren’s syndrome.
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INTRODUCTION
Sjögren’s syndrome (SS) is quite a common 
autoimmune disease evidenced by broad organ-specific 
and systemic manifestations. The most prevalent 
symptoms are diminished lacrymal and salivary gland 
function, xerostomia and keratoconjunctivitis sicca [1]. 
In addition, symptoms do not always occur concurrently. 
Primary SS (pSS) presents alone, and secondary SS 
(sSS) occurs in connection with other autoimmune 
rheumatic disease. This diversity of symptomatic 
expression adds to the difficulty in the initial diagnosis, 
and to the identification of homogenous group of 
patients with a uniform aetiopathogenesis or prognosis. 
The purpose of present paper is to critically address 
the recent advances and own clinical opinion on 
diagnostic procedures of Sjögren’s syndrome, taking 
into account the attained local and systemic features of 
the disease. 
MATERIAL AND METHODS
A comprehensive review of the available literature 
between 1970 and 2012, regarding to the diagnostic 
approaches to SS was conducted. Eligible studies 
were identified by searching the electronic literature 
PubMed, Medline, Embase, and ScienceDirect 
databases for relevant reports (last search update 
January 2012), combining the MESH heading term 
“Sjögren’s syndrome”, with the words “diagnosis, 
diagnostic procedures, salivary gland function, ocular 
tests, histopathology, salivary gland imaging, serology”. 
The authors checked the references of the selected 
articles to identify additional eligible publications 
and contacted the authors, if necessary. Present article 
addresses the established diagnostic criteria for SS 
and critically evaluates the most commonly used 
diagnostic procedures. However, it is not possible to 
comprehensively discuss every subject, because that 
would require a text too extensive for a single article. 
When appropriate, references are cited.
Diagnosis of Sjögren’s syndrome
The early and accurate establishment of a correct 
diagnosis of SS can assist on the prevention and timely 
treatment of many complications associated with the 
disease’s natural course. 
Although minor salivary gland biopsy has been 
traditionally considered “the gold standard” for 
the diagnosis of SS, newer criteria have emerged 
to assist on this disease identification. In 1993, 
the Preliminary European Classification criteria for 
SS were proposed and have been widely used, both 
in research and in clinical practice [2]. Later on, in 
2002, the criteria were re-examined and the revised 
version, published by the American Consensus Group, 
has led to the “American-European Consensus Group 
Criteria – revised international classification criteria for 
Sjögren’s syndrome” criteria set [3]. The established 
criteria became the most used tool in clinical trials and 
epidemiological surveys, addressing the classification of 
SS, both in primary and secondary entities. Moreover, 
due to addressed high sensitivity and specificity, they 
also became of clinical use in the diagnosis of the 
disease [4]. The classification system is presented on 
Table 1. In this score, 6 different items for each patient 
are considered (ocular symptoms, oral symptoms, eye 
tests, lip biopsy, imaging or function investigation of 
the salivary glands and antibodies in the blood) and if 
4 or more items are positive, the patient is considered 
to fulfil the classification criteria for SS. Interestingly, 
some particular diagnostic difficulties can arise from 
the use of this classification system. For instance, 
a patient who does not meet the criteria for salivary gland 
involvement and does not report both eye signs and eye 
symptoms, even in the situation of the fulfilment of 
4 items, would be better classified as having a focal 
lymphocytic sialadenitis, instead of SS. Comparing 
the patients who only report ocular and oral signs 
and symptoms, and have been diagnosed as having 
keratoconjunctivitis sicca and xerostomia might be 
overdiagnosed with SS.
An alternative classification for diagnosing SS was 
proposed by a Japanese expert group. This has been 
initially published in the late 1970’s, and revised in 
1999 [5]. These criteria, being mainly objective, address 
four major areas: histopathology, oral examination, 
ocular examination, and serological examination. 
The classification system is presented on Table 2.
The diagnosis of SS can be made when the patient 
meets at least two of these four criteria. These criteria 
have been shown to report a high sensitivity, specificity 
and accuracy for diagnosing SS [6].
Following, the major signs, symptoms and tests 
commonly used for the diagnosis of SS are presented 
and critically appraised. 
Ocular and oral symptoms
Symptoms from the eyes (item I) and from the oral cavity 
(item II) are highly regarded in the American-European 
Consensus Group Criteria for SS diagnosis. In these 
criteria, by responding affirmatively to at least one of 
the three predefined questions for the function of each 
exocrine gland, two items are readily checked positive. 
This means that 2 out of 4 items, half of the requirements 
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for the SS criteria, are based on a subjective analysis 
difficult to translate into quantifiable data. Nonetheless, 
it is routinely found that specific groups of patients 
(for instance, children and adolescents, or individuals 
experiencing chronic discomfort and distress) quite 
often deny having symptoms, nevertheless objective 
tests for dysfunction of the assayed exocrine glands 
(item II and III) give abnormal results [7]. This might 
be related to the fact that these individuals accept 
discomfort as a normal condition – as most may have 
felt it for most of their lives – and curtail its diagnostic 
relevance. 
The authors converge into a position more close to 
the one of the Japanese expert group, stating that 
the symptomatology should not be included into 
the classification criteria for SS diagnosis, but should be 
highly regarded in the complex treatment of SS.
Ocular testing
The Schirmer test for the eye quantitatively measures 
tear formation via placement of filter paper in the lower 
conjunctival sac [8]. Standardized paper strips (with 
5 mm width and 35 mm length) should be used and 
placed in the lower eyelids. Schirmer test without 
anaesthesia or Schirmer I (STI), is a well-standardized 
test that measures the basal tear secretion with 
the conjunctival-lachrymal trigeminal reflex, while 
the procedure of the Basal Schirmer test (STB) is 
performed with anaesthesia and measures the basal 
Table 1. Revised international classification criteria for Sjögren’s syndrome, by the American-European Consensus Group 
Criteria, 2002
I – Ocular symptoms (at least one of the following symptoms)
•	 Daily, persistent troublesome dry eyes for more than 3 months
•	 Recurrent sensation of sand or gravel in the eyes
•	 Use of tear substitutes more than 3 times per day
II – Oral symptoms (at least one of the following symptoms)
•	 Daily feeling of dry mouth for more than 3 months 
•	 Recurrent or persistent swollen salivary glands, as an adult
•	 Need to drink liquids to aid swallowing dry food
III – Ocular signs (positive result from at least one of the following tests)
1. Schrimer’s I test, performed without anesthesia (< 5 mm in 5 minutes)
2. Rose Bengal score or other ocular dye score (> 4, according to van Bijstervald’s scoring system)
IV – Histopathology
•	 In minor salivary glands – biopsied from normal-appearing mucosa – focal lymphocytic sialoadenitis, evaluated by 
an expert histopathologist, with a focus score > 1 (defined as the number of lymphocytic foci containing more than 50 
lymphocytes, adjacent to normal-appearing mucous acini, per 4 mm2 of glandular tissue  
V – Salivary gland involvement (positive result from at least one of the following tests)
•	 Unstimulated whole salivary flow (< 1.5 ml in 15 minutes)
•	 Parotid sialography showing the presence of diffuse sialectasias
•	 Salivary scintigraphy showing delayed uptake, reduced concentration, and/or delayed excretion of tracer
VI – Autoantibodies (serum presence of the following autoantibodies)
•	 Antibodies to Ro (SSA) or La (SSB), or both, in the serum
Exclusion criteria
Past head and neck radiation treatment; Hepatitis C infection; Acquired immunodeficiency syndrome; Pre-existing 
lymphoma or sarcoidosis; Graft versus host disease; Use of anticholinergic drugs
Table 2. Revised Japanese Criteria for Sjögren’s Syndrome, 1999
I – Histopathology (positive for at least one of the following)
•	 Focus score ≥ 1 (periductal lymphoid cell infiltration ≥ 50) in a 4 mm2 minor salivary gland biopsy
•	 Focus score ≥ 1 (periductal lymphoid cell infiltration ≥ 50) in a 4 mm2 lacrimal gland biopsy
II – Oral Examination (positive for at least one of the following)
•	 Abnormal findings in sialography ≥ Stage I (diffuse punctate shadows of less than 1mm)
•	 Decreased salivary secretion (flow rate ≤ 10 ml/10 min according to the chewing gum test or ≤ 2 g/2 min according to 
the Saxon test) and decreased salivary function according to salivary gland scintigraphy
III – Ocular Examination (positive for at least one of the following)
•	 Schirmer’s test ≤ 5 mm/5 min and Rose Bengal test ≥ 3 according to the van Bijsterveld score
•	 Schirmer’s test ≤ 5 mm/5 min and positive fluorescein staining test
IV – Serological Examination (positive for at least one of the following)
•	 Anti-Ro/SS-A antibody
•	 Anti-La/SS-B antibody
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lachrymal secretion [9]. Other variations of the Schirmer 
test are less frequently used in SS diagnosis. 
In STI, the strip is placed in the lower fornix between 
the medial and lateral third of the eyelid of the 
unanaesthetised eye. After 5 minutes, the amount of 
wetting is measured from the extrafornical position of 
the strip [10]. According to both the Revised 
International Classification Criteria for Sjögren’s 
syndrome and the Japanese criteria, if less than 5 mm 
of paper are wetted following 5 minutes of the STI test, 
the result of the test is considered positive. In Figure 1, 
the STI test and its results, conducted on a SS-affected 
individual, are shown.
Alternatively, positive ocular surface Rose Bengal or 
other ocular dye score, (i.e., fluorescein vital staining, 
lissamine green, etc.) can also be conducted. These 
tests are most commonly used for the evaluation of 
ocular surface epithelial damage, since these vital 
stains mark cells, on the surface of the eye, that are 
not fully coated by the mucin layer of tear fluid and/
or are damaged. The Rose Bengal score, a quantified 
version of the original Rose Bengal test, is commonly 
used to quantify the degree of staining [8,11]. 
The test is conducted by the application of a 1% 
solution of Rose Bengal, within the inferior fornix of 
both eyes. The patient should be following asked to 
make one or two full blinks. The examiner uses white 
light to assess the amount of staining, in the two exposed 
conjunctival zones (medial and lateral) and cornea. 
Each section is scored up to 3 points, according to the 
Van Bijsterveld score: 1, sparsely scattered spots; 2, 
densely scattered spots; and 3, confluent spots). While 
the maximum score is 9, a score of 4 or more, or 3 or 
more, was considered diagnostic of SS, according to the 
International classification criteria, or Japanese criteria 
for SS, respectively. In patients with SS, Rose Bengal 
staining can cause the eyes to sting and the test may be
painful. Scoring with lissamine green stain is less 
painful, but more difficult to evaluate.
The tear break up time (BUT) test aims to measure 
the quality of the tear fluid [8]. It is defined as the 
interval between a complete blink and the appearance of 
the first randomly distributed dry spots. Usually, a 1% 
fluorescein solution is carefully placed in the inferior 
fornix of both eyes. The patient is then asked to blink 
a few times, and then, it is examined how long the tear 
film remains evenly distributed over the surface of 
the cornea [11]. The tear film normally remains intact 
for 10 seconds or longer, being highly abnormal in SS-
affected individuals. 
Laser scanning confocal microscopy (LSCM) has 
been recently used as an efficient, noninvasive, in vivo 
and fast tool to quantitative assess the conjunctival 
inflammation and epithelial cell densities, as well as 
the evaluation of conjunctival morphologic alterations 
in patients with SS [12]. Furthermore, LSCM may be 
a valuable tool in monitoring the progress and the 
follow-up of patients with Sjögren’s syndrome dry eye 
[13].
According to the reported criteria for SS diagnosis, 
the Revised International Classification Criteria 
substantiates that of the various tests that can be 
performed, only one single abnormal result is 
sufficient for the objective evidence of lachrymal gland 
involvement. On the contrary, the Japanese expert group 
agreed on that at least two objective tests for determining 
lachrymal gland involvement should be conducted and 
report abnormal results. While the authors converge to 
the need of test validation, and thus the requirement of at 
least two abnormal test results to claim the affection of 
lachrymal glands, it is clear that the STI test has the great 
advantage that can be easily conducted within the dental 
office while other ocular tests require the assistance of 
a certified ophthalmologist.
Figure 1. STI test (A) and test results (B) revealing a significant reduction in lachrymal secretion.
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Histopathological analysis
Minor salivary gland biopsy remains a highly used 
diagnostic procedure for the salivary component of 
SS. This is usually performed on the internal face of 
the lower lip on normal-appearing mucosa. Under 
local anaesthesia an incision of around 1.5 to 2 cm is 
made between midline and the commissure, through 
the mucosa with penetration of the epithelium. With this 
procedure, usually 5 or more minor salivary glands are 
excised. The biopsy contributes towards the diagnosis of 
SS if the histopathological examination reveals 
a mononuclear infiltration with periductal or perivascular 
distribution. The inflammatory infiltrate is quantified 
and a cluster of ≥ 50 lymphocytes is termed a focus. 
The numbers of focus in an area of 4 mm² of tissue surface 
render the focus score. A focus score ≥ 1, as according 
to both the Revised International Classification Criteria 
and the Japanese expert criteria, are considered positive 
for SS diagnosis. 
As an example, salivary gland tissue from a patient with 
Sjögren’s syndrome, with a focus score greater than 4, 
is shown in Figure 2.
Minor salivary gland lip biopsy results, nonetheless 
reporting a useful diagnostic value in SS, should be 
carefully addressed in the overall diagnostic procedure 
due to inconsistencies of sensitivity and specificity. 
A false negative result range from around 20 to 40% 
and also positive biopsy results have been found up 
to 10% of healthy individuals [14]. In one study, 
abnormal biopsies (with a focus score ranging from 
2 to 6) have been found in 15% of healthy volunteers 
with no subjective xerostomia or dry eyes [15]. Also, 
patients affected by myasthenia gravis, sialolithiasis 
and other autoimmune disorders not associated with 
sicca symptoms may also reveal minor salivary gland 
infiltration [16]. Other factors can also affect focus 
score determination; cigarette smoking is negatively 
associated with sialadenitis focus score > 1, in patients 
with primary Sjögren’s syndrome [17]. Lip biopsies 
analysis has also been found to induce a poor inter-
rater reliability in histopathological analysis, in terms 
of diagnostic status, focus scores and histological 
characteristics [18]. The extents of infiltrates in a lip 
biopsy using the same methodological approach may 
vary greatly from gland to gland in a single patient. 
Further, if the density of infiltrate is severe, the foci may 
become confluent, hindering focus score determination. 
These and other factors may converge to justify that, in 
one study, a second evaluation of the histopathological 
analysis of labial salivary glands biopsies significantly 
changed the initial diagnosis in 32 of 60 studied cases 
(53%) [19]. 
In a different approach, and apart from the diagnostic 
Figure 2. Labial salivary gland biopsy consistent with Sjögren’s 
syndrome, showing multiple lymphocytic foci (black arrow) and 
intact acinar units (white arrow) (hematoxylin and eosin stain, 
original magnification x100).
value, the performance of lymphoid organization in the 
form of germinal centre-like lesions in labial salivary 
gland biopsies, taken at SS diagnosis, was proposed as a 
highly predictive marker for non-Hodgkin’s lymphoma 
development – associated with a high risk of mortality 
in pSS-affected individuals [20]. 
Alternative biopsy techniques have also been 
proposed on the assessment of pSS diagnosis. In one 
study, parotid biopsy was shown to have a diagnostic 
potential comparable with that of a labial biopsy and 
could further be associated with less morbidity [21]. 
Additionally, in a case report where the patient revealed 
ocular and oral symptoms and signs, but did not meet 
the SS classification criteria according to the Revised 
International Classification Criteria (no anti-SSA or 
anti-SSB antibodies were detected, and minor salivary 
gland biopsy was normal), parotid gland biopsy was 




Sialometry aims to measure the saliva flow function, and 
can be conducted with whole saliva, saliva obtained from 
a specific gland, both with or without stimulation. Whole 
saliva tests are generally easier and more conveniently 
performed. For a diagnosis of hyposalivation, 
the unstimulated whole saliva flow rate (UWSFR) has 
been proposed as the test of choice, as it may be reduced, 
even if the stimulated whole saliva is unaffected [23]. 
Unstimulated collection is conducted by the recovery 
of saliva in a grading tube by a predetermined period – 
usually 5 or 15 minutes. Values inferior to 0.1 mL/min 
are considered abnormal [24]. This test quantifies saliva 
secretion from all salivary glands and is believed to 
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show alterations at the early stages of the disease, being 
highly reproducible [25]. According to the Revised 
International Classification Criteria, the unstimulated 
whole saliva produced over a period of 15 minutes, 
without the subjects have eaten or smoked for at 
least 2 hours, should be measured. A result inferior to 
1.5 ml would transpose to a positive test result. Many 
researchers, including the authors, consider the testing 
time excessively long, with alternative techniques 
considering shorter periods being equally validated 
[26,27]. This comes in line with the Japanese criteria 
which rely on the assessment of stimulated whole saliva 
tests as they shows less examiner associated bias. 
Stimulated saliva assessment can be complicated in 
patients who do not tolerate the stimulus of salivation 
and, moreover, due to the wide variety of used 
stimulus (i.e., citric acid, gum, paraffin etc.) there is 
a generalized lack of agreement for normal values. 
A flow rate inferior to 10 ml/10 minutes, in the chewing 
gum test, is considered positive in the Japanese criteria. 
Alternatively, these criteria refer to the Saxon test, 
in which a 10 x 10 gauze sponge should be weighted 
and used for saliva collection by vigorous chewing for 
2 minutes. The amount of saliva produced is determined 
by subtracting the original weight from the weight 
obtained after chewing. In the Japanese criteria, a value 
inferior to 2 g/2 minutes is considered positive.
Collection of the stimulated parotid saliva, and 
subsequent assessment of the flow rate, can be 
conducted with the requirement of special suction 
cups placed over the Stensen duct. Stimulated saliva 
is usually collected for 3 minutes and values inferior 
to 0.5 mL/min are considered abnormal [24]. Despite 
the high sensitivity, the stimulated parotid saliva 
sialometry may fail to reveal alterations at the initial 
stages of the disease, requires special equipment and 
may not be easily tolerated by patients [28].
The lower lip mucosa is dried for 5 min expecting 
the small saliva drops to occur. The width of the drop 
less than 1mm is considered to show hipofunction. This 
test is easy to perform, but still needs more investigation 
to be included in SS classification criteria instead of 
lower lip biopsy [29].
Several authors also highlight to the variation found in 
sensitivity and specificity (ranging from around 45 to 
82%, and from 60 to 92%, respectively) of sialometry 
in SS diagnosis [14]. In fact, salivary secretion is 
dependent on many factors including time of the day, 
circadian rhythm, degree of hydratation, body position, 
smoking, sex, age, body mass, exposure to light and 
multiple medications [30]. This is also clear that there 
might be no obvious correlations of oral dryness with 
the measurements of saliva function. Critical salivation 
level to occur dryness is dependent upon person and 
may be related to relative diminishion of saliva above 
50%. 
Nonetheless, it is the authors’ inkling that salivary flow 
should be routinely performed, not only as part of SS 
diagnosis, but also as part of patient monitoring. 
Sialography
This study requires the radiographic imaging of 
a salivary gland (usually the parotid), following 
the retrograde injection of a contrast medium through 
the excretory duct. The medium is distributed through 
the duct system, allowing the analysis of the architecture 
and configuration of the glandular ducts’ organization. 
In SS-affected patients it can be verified a dilatation and 
twisting of the ducts, with an uneven distribution of 
the contrast medium, broadly originating the appearance 
of a branching pattern of the ducts. A positive result 
in the sialographic study is part of both the Revised 
International Classification criteria and Japanese criteria 
for the SS diagnosis. 
Sialography may be technically challenging, time-
consuming, painful and risky. In fact it is contraindicated 
in severe gland dysfunction due to the risk of indefinitely 
retaining the contrast medium [31,32]. Sialography has 
been shown to have a high accuracy in the diagnosis 
of SS, nonetheless sialectasis may also be found in 
healthy individuals, as well as in individuals affected 
by other diseases like chronic sialadenitis [14]. Also, 
several reports showed that that the diagnostic value of 
parotid sialography for diagnosing SS greatly depends 
on the skills of the observer [33]. Nonetheless, given 
the potentially high sensitivity and specificity in SS 
diagnosing, as well as its useful staging potential, 
sialography still has its use in the evaluation of the 
oral component of SS. Diagnosis is generally based on 
the classification of Rubin and Holt [34] in which stage 
0 (normal) corresponds to no contrast media collection; 
stage 1 (punctate) refers to contrast media collection 
≤ 1 mm in diameter; stage 2 (globular) refers to contrast 
media collection between 1 and 2 mm in diameter; 
stage 3 (cavitary) refers to contrast media collection 
≥ 2 mm in diameter; and stage 4 (destructive) refers to 
the complete destruction of the gland parenchyma.
A sialography of a SS-affected patient (Stage 3) 
5 minutes following the injection of the contrast medium 
is reported in Figure 3.
Scintigraphy
The scintigraphy is a non-invasive method to evaluate 
the function of salivary glands by addressing 
the uptake and secretion of a radioactive labelled 
substance (sodium pertechnate of 99mTc). Additionally, 
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Figure 3. Sialographic imaging of the parotid gland (Stage 3, according the 
Rubin and Holt classification). A = frontal view; B = lateral view. Note the dilated 
main duct and the sparse overall branching pattern of the ducts.
acceptance of such criteria still remain to be 
established. In which relates to SS, a recent 
report has shown a correlation between the 
severity of the scintigraphic involvement 
and a more pronounced autoimmune 
involvement with an increased risk to 
develop systemic features, lymphoma, and 
a lower survival rate [37]. Other reports also 
substantiate the relevance of scintigraphy in 
the assessment of glandular dysfunction and of 
the disease severity [38,39]. The authors 
corroborate the relevance of the scintigraphic 
study at SS diagnosis, due to the valuable 
clinical information on the prognosis and 
outcome of both pSS and sSS.
However, this technique needs special 
equipment and staff that can only be found 
in reference clinical centers. Further, it may 
an abnormal salivary gland scintigraphy result is 
accepted by the American - European consensus group 
as a criterion for the diagnosis of Sjögren’s syndrome. 
Normally, a rapid uptake and increased concentration of 
the radioactive probe is attained in the salivary glands 
(it can normally be seen within 10 minutes following 
intravenous administration). After 20 - 30 minutes, 
the substance is rapidly secreted into the mouth. Salivary 
flow may be stimulated with the use of a sialogogue 
(e.g., diluted lemon juice) administered to the dorsal 
tongue. Time-activity curves are calculated using 
manually drawn oval regions-of-interest around both 
the parotid and the submandibular glands. In Sjögren’s 
syndrome, lower concentration and less secretion into 
the mouth are seen. The test reports a high sensitivity 
but a low specificity in SS diagnosis.
Scintigraphy data results are expressed as quantitative 
values, which are transformed to semi qualitative 
indices. But generally in practice qualitative and 
observer-dependent classification is used to present 
the results and to search for clinical correlations. 
Schall’s categorical classification is usually considered 
the standard method for salivary scintigraphy 
interpretation, though subjective and with limited 
capacity to discriminate borderline results [35]. In this 
classification system, the uptake and discharge of the 
radioactive probe is visually evaluated, and the glands 
are individually graded from 1 (normal) to 4 (severe 
affection) [36]. Accordingly, several quantifiable indices 
of salivary function have been proposed including 
the rate of trapping and uptake, time of maximum 
activity, uptake ratios and magnitude or rate of 
stimulated salivary discharge [35]. Nonetheless, 
few studies evaluated the centrality and dispersion 
of these quantitative scintigraphic indices in well-
characterized groups of controls, and the validity and 
be unacceptable for the patient due to risk of radiation 
damage and high cost.
A scintigraphic study of the salivary glands of an SS-
affected patient is shown in Figure 4.
Magnetic Resonance (MR) and ultrasonography (US)
MR imaging (MRI), MR sialography and US are 
noninvasive methodologies that allow the imaging of 
salivary glands in their physiological state without 
artefacts induced by intraductal contrast media or 
biopsy procedures. Further, these imaging modalities 
allow a reduction in the inconveniences and risk of 
complications to the patient [40]. Recent advances 
in technical equipment allowed for the yield of such 
a definitive picture of the glandular structural changes 
that they are promising alternatives to conventional 
examinations. 
MR imaging was shown to provide a reliable imaging 
procedure to evaluate glandular alterations. It allows 
multiplanar evaluation and processes a high contrast 
tissue resolution. Characteristically, in SS, MRI reveals 
an inhomogeneous internal pattern on both T1 and 
T2 sequences, with multiple hypo- and hyper-intense 
nodules of different sizes [40]. MRI quantitative 
analysis for the standard deviation of the signal intensity 
was found to be useful in SS diagnosis. The signal 
intensity in T1-weighth parotid MR images was found 
to increase proportionally to the severity of the disease 
[41]. Further, other MR modalities in the SS assessment 
have been used, including MR sialography, functional 
MR sialography, and dynamic contrast-enhanced MRI. 
The latter and tracer kinetic modelling were used to 
quantify the altered microvascular pathophysiologic 
features of salivary glands in SS [42]. SS-affected 
patients were shown to report a great differentiation and 
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Figure 4. Scintigraphic study of the salivary glands (class IV, according to the Schall’s classification). The right parotid gland is encircled 
in red, the left parotid gland is encircled in green, the right submandibular gland is encircled in blue and the left submandibular gland 
is encircled in yellow. Time-activity curves are presented on the right and each colour corresponds to the previously encircled glands, 
respectively. Note the severe functional affection with a significant reduction in the uptake of the radioactive probe and absence of the 
discharge phase, even after the stimulation with a sialogogue (red line at 9 minutes).
an increased heterogeneity in microvascular parameters, 
comparing to controls [42].
MR sialography has largely replaced conventional 
sialography in the latter years and can produce 
sialographic images similar to those of conventional 
sialography without the use of contrast media or 
radiation. The underlying principles are set on 
the use of a protocol that uses a heavily T2-weighted, 
fat-suppressed pulse sequence and rapid acquisition 
with relaxation enhancement [43]. It has been found 
to be highly accurate and sensitive in the evaluation of 
salivary gland disease in SS [44]. Furthermore, dynamic 
MR sialographic images and data were also shown to be 
useful in the diagnosis of patients with SS. Significant 
reduced values have been found regarding the maximum 
area and the ratio of change in the detectable ducts, in 
SS-affected patients, comparing to control [45,46].
Salivary ultrasonography (US) is a noninvasive and 
low cost imaging technique that has been recently 
used in the diagnosis and staging of SS. US is more 
effective on the parotid gland and less helpful in 
the assessment of other salivary glands. Moreover, it 
is a technique highly operator-dependent [47]. Despite 
these characteristics, US detection of parenchymal 
inhomogenicity of the major salivary glands and 
observation of reduced volume of the submandibular 
glands resulted in high specificities for diagnosis of pSS 
and sSS [48]. Characteristic US features of SS include 
an inhomogeneous structure of the gland (early stages), 
with scattered multiple small, oval, hypoechoic or 
anechoic areas of lymphocytic infiltrates (intermediate 
stages), and the presence of echogenic lines – fibrosis 
– that converge into a glandular reticular pattern (late 
stages) usually well defined. Other features, though 
more uncommonly found, may include the dilatation of 
the main duct, increased parenchymal blood flow 
(accessed by Doppler), pseudo masses, irregular cystic 
masses, and intraparotid lymph node enlargement 
[48]. Recent reports converge to the relevance of 
the diagnostic value of US and substantiate its use over 
more invasive methodological approaches [49,50].
An US of the parotid and submandibular glands is 
shown in Figure 5.
The authors come together to the relevance of 
the available noninvasive imaging modalities in 
the assessment of salivary gland involvement in SS, 
despite the acknowledgement that comparative large-
scale multicenter studies should be conducted to 
confirm the relation between diagnostic value and cost-
effectiveness in SS.
Sialochemistry
Sialochemistry involves the analysis of salivary 
composition, both including organic and inorganic 
constituents, by means of different biochemical, 
electrophoretic and immunological analytical methods. 
They aim to address the injuries submitted to salivary 
glands regarding secretion content. Various parameters 
have been evaluated and the salivary protein profile of 
SS is a mixture of increased inflammatory proteins and 
decreased acinar proteins when compared to healthy 
controls [51,52]. Moreover, proteomic approaches 
have also been conducted on the saliva of SS patients. 
Differences regarding protein expression were found 
between SS patients and healthy subjects. However, 
individual analysis of SS patients exhibited distinct 
patterns of protein expression and did not correlate 
with the clinical, serological or histological severity of 
disease [53-55]. Also ionic changes were observed in 
SS-affected individuals, namely regarding the levels of 
chloride, potassium, calcium, sodium and magnesium 
[28,56]. Despite attained variations, sialochemistry 
is considered nondiscriminatory and of no diagnostic 
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Figure 5. Gray-scale (A) and a power Doppler (B) US images showing advanced-stage Sjögren’s syndrome in salivary glands. The gland 
has an inhomogeneous structure with multiple small, oval, hypoechoic areas (arrowheads) and increased blood flow. The position of the US 
probe is shown in the inset diagram. A = imaging of the right parotid gland; B = imaging of the left submandibular gland.
A B
relevance due to the attained inter-individual variation 
in both SS-affected patients and healthy controls, lack of 
standardization in saliva collection and regarding 
analytical procedures. Furthermore, some SS patients 
produce little or no saliva which limits sialochemistry 
applications. 
Plasmatic and serologic markers
Patients affected by SS usually present a wide 
range of serologic and laboratory findings, ranging 
from cytopenias (e.g., anaemia, leukopenia, 
thrombocytopenia), hypergammaglobulinemias 
(usually of the IgG class, and more rarely of the IgA 
and IgM classes), high erythrocyte sedimentation 
rate and C-protein levels, and autoantibodies [57,58]. 
Of the latter, antinuclear antibodies (ANAs) is 
the most frequently detected, while anti-Ro/SS-A is 
the most specific (despite occurring in other autoimmune 
disorders), and cryoglobulins and hypocomplementemia 
is the main prognostic markers [59]. 
Positive autoantibodies are one the attained 
classification criteria for SS in both the Revised 
International Classification and the Japanese Revised 
criteria, being the only analytical data included. 
The 1993 European Criteria include the presence of one 
or more of ANAs, rheumatoid factor (RF), Ro/SS-A, 
and/or La/SS-B, while the 2002 Criteria include only 
anti-Ro/SS-A and/or anti-La/SS-B antibodies. ANAs 
are the most frequently detected auto-antibodies in pSS 
and are closely associated with various extraglandular 
and analytical SS features [60], as RF, which is 
broadly associated with the main extraglandular, 
histopathologic, haematologic, and immunologic SS 
feature [61,62]. In fact ANAs and RF have shown to 
possess predictive and prognostic values for those 
patients who do not fulfil the higher stringent 2002 
revised criteria but are indicated for immunomodulatory 
therapy [61]. The authors substantiate that ANA and RF 
determinations may play a central role in diagnosis of 
SS, especially in those patients with suspected evidences 
but failing to fulfil the classification criteria. 
Despite the relevance of ANAs and RF, the most widely 
used biomarkers of SS are still serum IgG autoantibodies 
against two nuclear proteins, Ro-52/SSA and La/SSB. In 
clinical setting, these antibodies are measured in serum 
for diagnostic purpose. IgG anti-La/SSB antibodies 
represent the major serum antibody class, whereas IgA 
and IgM are rarely detected. IgG antibodies, rarely IgA, 
are also detected in saliva from patients with SS. As for 
anti-Ro/SSA, IgG remains to be the main class while 
IgA and IgM classes have not been identified [63]. Some 
other autoantibodies, including anti-α-fodrin antibody, 
anti-type 3 muscarinic acetylcholine receptor and anti-
centromere antibodies were also found to be associated 
with pSS [64-66]. Nonetheless, their specificity and 
sensitivity is inferior to classic assessed markers (Ro-
52/SSA and La/SSB).
Several studies have also found that patient with 
hypocomplementemia and cryoglobulins at diagnosis 
were shown to possess a higher risk of developing 
vasculitis and B-cell lymphoma during follow-up, and 
that the presence of these markers reported to be a key 
prognostic value in patient survival [67,68]. Verified 
hypocomplementemia may be due to the complement 
activation caused by cryoglobulinemia.
CONCLUSIONS
Sjögren’s syndrome is a common autoimmune disease 
of which the diagnosis and treatment are frequently 
delayed. Due to its systemic involvement, it can exhibit 
a wide range of clinical manifestations that contribute 
to confusion and delay in diagnosis. An increased 
awareness of SS and its many and varied manifestations 
encourages a more expansive approach to diagnosing 
this disease. The use of recently refined criteria for 
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diagnosis can assist in identifying patients with SS early. 
Particularly, due to the fact that there is no simple and 
validated test for SS diagnosis and the need for an easy, 
low-cost and straightforward test for the assessment of 
the oral component of SS, is still highly demanded.The 
use of all available diagnostic modalities will help to 
reduce the time to diagnosis and preserve the health and 
quality of life of patients with SS. 
ACKNOWLEDGMENTS AND DISCLOSURE 
STATEMENTS
The authors declare that they have no conflict of 
interests.
REFERENCES
1. Fox RI. Sjögren’s syndrome. Lancet. 2005 Jul 23-29;366(9482):321-31. Review. [Medline: 16039337] 
[doi: 10.1016/S0140-6736(05)66990-5]
2. Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, Bjerrum KB, Braga S, 
Coll J, de Vita S, et al. Preliminary criteria for the classification of Sjögren’s syndrome. Results of a prospective 
concerted action supported by the European Community. Arthritis Rheum. 1993 Mar;36(3):340-7. [Medline: 8452579] 
[doi: 10.1002/art.1780360309]
3. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, 
Kassan SS, Pillemer SR, Talal N, Weisman MH; European Study Group on Classification Criteria for Sjögren’s 
Syndrome. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by 
the American-European Consensus Group. Ann Rheum Dis. 2002 Jun;61(6):554-8. Review. [Medline: 12006334] 
[doi: 10.1136/ard.61.6.554] [FREE Full Text]
4. Baldini C, Talarico R, Tzioufas AG, Bombardieri S. Classification criteria for Sjogren’s syndrome: A critical review. J 
Autoimmun. 2011 Dec 30. [Epub ahead of print] [Medline: 22209352] [doi: 10.1016/j.jaut.2011.12.006]
5. Fujibayashi T, Sugai S, Miyasaka N, Toujou T, Miyawaki M, Ichikawa Y. Revised Japanese Creteria for Sjögren’s 
syndrome. Tokyo 1999. p. 135-9.
6. Fujibayashi T, Sugai S, Miyasaka N, Hayashi Y, Tsubota K. Revised Japanese criteria for Sjögren’s syndrome (1999): 
availability and validity. Mod Rheumatol. 2004 Dec;14(6):425-34. [doi: 10.1007/s10165-004-0338-x]
7. Bartůnková J, Sedivá A, Vencovský J, Tesar V. Primary Sjögren’s syndrome in children and adolescents: proposal for 
diagnostic criteria. Clin Exp Rheumatol. 1999 May-Jun;17(3):381-6. [Medline: 10410277]
8. Paschides CA, Kitsios G, Karakostas KX, Psillas C, Moutsopoulos HM. Evaluation of tear break-up time, Schirmer’s-I 
test and rose bengal staining as confirmatory tests for keratoconjunctivitis sicca. Clin Exp Rheumatol. 1989 Mar-
Apr;7(2):155-7. [Medline: 2736828] 
9. Cho P, Yap M. Schirmer test. I. A review. Optom Vis Sci. 1993 Feb;70(2):152-6. Review. [Medline: 8446379] 
[doi: 10.1097/00006324-199302000-00011]
10. Cho P, Yap M. Schirmer test. II. A clinical study of its repeatability. Optom Vis Sci. 1993 Feb;70(2):157-9. 
[Medline: 8446380] [doi: 10.1097/00006324-199302000-00012]
11. Vitali C, Moutsopoulos HM, Bombardieri S. The European Community Study Group on diagnostic criteria for Sjögren’s 
syndrome. Sensitivity and specificity of tests for ocular and oral involvement in Sjögren’s syndrome. Ann Rheum Dis. 
1994 Oct;53(10):637-47. [Medline: 7979575] [doi: 10.1136/ard.53.10.637] [FREE Full Text]
12. Wakamatsu TH, Sato EA, Matsumoto Y, Ibrahim OM, Dogru M, Kaido M, Ishida R, Tsubota K. Conjunctival in vivo 
confocal scanning laser microscopy in patients with Sjögren syndrome. Invest Ophthalmol Vis Sci. 2010 Jan;51(1):144-
50. Epub 2009 Aug 20. [Medline: 19696170] [doi: 10.1167/iovs.08-2722] [FREE Full Text]
13. Hong J, Zhu W, Zhuang H, Xu J, Sun X, Le Q, Li G, Wang Y. In vivo confocal microscopy of conjunctival goblet 
cells in patients with Sjogren’s syndrome dry eye. Br J Ophthalmol. 2010 Nov;94(11):1454-8. Epub 2009 Dec 2. 
[Medline: 19955202] [doi: 10.1136/bjo.2009.161059] 
14. Soto-Rojas AE, Kraus A. The oral side of Sjögren syndrome. Diagnosis and treatment. A review. Arch Med Res. 2002 
Mar-Apr;33(2):95-106. Review. [Medline: 11886706] [doi: 10.1016/S0188-4409(01)00371-X]
15. Radfar L, Kleiner DE, Fox PC, Pillemer SR. Prevalence and clinical significance of lymphocytic foci in minor salivary 
glands of healthy volunteers. Arthritis Rheum. 2002 Oct 15;47(5):520-4. [Medline: 12382301] [doi: 10.1002/art.10668] 
[FREE Full Text]
16. Vitali C, Tavoni A, Simi U, Marchetti G, Vigorito P, d’Ascanio A, Neri R, Cristofani R, Bombardieri S. Parotid 
sialography and minor salivary gland biopsy in the diagnosis of Sjögren’s syndrome. A comparative study of 84 patients. 
J Rheumatol. 1988 Feb;15(2):262-7. [Medline: 3258917]
17. Manthorpe R, Benoni C, Jacobsson L, Kirtava Z, Larsson A, Liedholm R, Nyhagen C, Tabery H, Theander E. Lower 
frequency of focal lip sialadenitis (focus score) in smoking patients. Can tobacco diminish the salivary gland involvement 
as judged by histological examination and anti-SSA/Ro and anti-SSB/La antibodies in Sjögren’s syndrome? Ann Rheum 
Dis. 2000 Jan;59(1):54-60. [Medline: 10627428] [doi: 10.1136/ard.59.1.54] [FREE Full Text]
http://www.ejomr.org/JOMR/archives/2012/1/e3/v3n1e3ht.htm J Oral Maxillofac Res 2012 (Jan-Mar) | vol. 3 | No 1 | e3 | p.11
(page number not for citation purposes)
JOURNAL OF ORAL & MAXILLOFACIAL RESEARCH                                                                  Gomes et al. 
18. Stewart CM, Bhattacharyya I, Berg K, Cohen DM, Orlando C, Drew P, Islam NM, Ojha J, Reeves W. Labial salivary 
gland biopsies in Sjögren’s syndrome: still the gold standard? Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 
Sep;106(3):392-402. Epub 2008 Jul 7. [Medline: 18602295] [doi: 10.1016/j.tripleo.2008.04.018]
19. Vivino FB, Gala I, Hermann GA. Change in final diagnosis on second evaluation of labial minor salivary gland biopsies. 
J Rheumatol. 2002 May;29(5):938-44. [Medline: 12022353]
20. Theander E, Vasaitis L, Baecklund E, Nordmark G, Warfvinge G, Liedholm R, Brokstad K, Jonsson R, Jonsson MV. 
Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant 
lymphoma in primary Sjögren’s syndrome. Ann Rheum Dis. 2011 Aug;70(8):1363-8. [Medline: 21715359] 
[doi: 10.1136/ard.2010.144782] [FREE Full Text]
21. Pijpe J, Kalk WW, van der Wal JE, Vissink A, Kluin PM, Roodenburg JL, Bootsma H, Kallenberg CG, 
Spijkervet FK. Parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary 
Sjogren’s syndrome. Rheumatology (Oxford). 2007 Feb;46(2):335-41. Epub 2006 Aug 5. [Medline: 16891656] 
[doi: 10.1093/rheumatology/kel266] [FREE Full Text]
22. Soyfoo MS, Catteau X, Delporte C. Parotid Gland Biopsy as an Additional Diagnostic Tool for Supporting the 
Diagnosis of Sjögren’s Syndrome. Int J Rheumatol. 2011;2011:302527. Epub 2011 Aug 7. [Medline: 21845192] 
[doi: 10.1155/2011/302527] [FREE Full Text]
23. Sreebny LM. Salivary flow in health and disease. Compend Suppl. 1989;(13):S461-9. Review. [Medline: 2691080]
24. Atkinson JC. The role of salivary measurements in the diagnosis of salivary autoimmune diseases. Ann N Y Acad Sci. 
1993 Sep 20;694:238-51. Review. [Medline: 8215059] [doi: 10.1111/j.1749-6632.1993.tb18357.x]
25. Sreebny L, Zhu WX. Whole saliva and the diagnosis of Sjögren’s syndrome: an evaluation of patients who complain 
of dry mouth and dry eyes. Part 1: Screening tests. Gerodontology. 1996 Jul;13(1):35-43. [Medline: 9452640] 
[doi: 10.1111/j.1741-2358.1996.tb00148.x]
26. Gotoh S, Watanabe Y, Fujibayashi T. Validity of stimulated whole saliva collection as a sialometric evaluation for 
diagnosing Sjögren’s syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Mar;99(3):299-302. [Medline: 
15716835] [doi: 10.1016/j.tripleo.2004.09.016]
27. López-Jornet P, Camacho-Alonso F, Bermejo-Fenoll A. A simple test for salivary gland hypofunction using Oral Schirmer’s 
test. J Oral Pathol Med. 2006 Apr;35(4):244-8. [Medline: 16519773] [doi: 10.1111/j.1600-0714.2006.00411.x]
28. Kalk WW, Vissink A, Stegenga B, Bootsma H, Nieuw Amerongen AV, Kallenberg CG. Sialometry and 
sialochemistry: a non-invasive approach for diagnosing Sjögren’s syndrome. Ann Rheum Dis. 2002 Feb;61(2):137-44. 
[Medline: 11796400] [doi: 10.1136/ard.61.2.137] [FREE Full Text]
29. Eliasson L, Carlén A. An update on minor salivary gland secretions. Eur J Oral Sci. 2010 Oct;118(5):435-42. Epub 2010 
Aug 24. Review. [Medline: 20831576] [doi: 10.1111/j.1600-0722.2010.00766.x]
30. Flink H, Tegelberg A, Lagerlöf F. Influence of the time of measurement of unstimulated human whole saliva on 
the diagnosis of hyposalivation. Arch Oral Biol. 2005 Jun;50(6):553-9. Epub 2004 Dec 15. [Medline: 15848148] 
[doi: 10.1016/j.archoralbio.2004.10.015]
31. Valdez IH, Fox PC. Diagnosis and management of salivary dysfunction. Crit Rev Oral Biol Med. 1993;4(3-4):271-7. 
Review. [Medline: 8373984] [doi: 10.1177/10454411930040030301]
32. Schortinghuis J, Pijpe J, Spijkervet FK, Vissink A. Retention of lipiodol after parotid gland sialography. Int J Oral 
Maxillofac Surg. 2009 Apr;38(4):346-9. Epub 2009 Jan 20. [Medline: 19157783] [doi: 10.1016/j.ijom.2008.12.007]
33. Kalk WW, Vissink A, Spijkervet FK, Bootsma H, Kallenberg CG, Roodenburg JL. Parotid sialography for diagnosing 
Sjögren syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Jul;94(1):131-7. [Medline: 12193907] 
[doi: 10.1067/moe.2002.126017]
34. Rubin P, Holt J. Secretory sialography in diseases of the major salivary glands. Am J Roentgenol Radium Ther Nucl 
Med. 1957 Apr;77(4):575-98. [Medline: 13411334]
35. Vinagre F, Santos MJ, Prata A, da Silva JC, Santos AI. Assessment of salivary gland function in Sjögren’s 
syndrome: the role of salivary gland scintigraphy. Autoimmun Rev. 2009 Jul;8(8):672-6. Epub 2009 Feb 24. Review. 
[Medline: 19245858] [doi: 10.1016/j.autrev.2009.02.027]
36. Schall GL, Anderson LG, Wolf RO, Herdt JR, Tarpley TM Jr, Cummings NA, Zeiger LS, Talal N. Xerostomia in Sjögren’s 
syndrome. Evaluation by sequential salivary scintigraphy. JAMA. 1971 Jun 28;216(13):2109-16. [Medline: 4932139] 
[doi: 10.1001/jama.1971.03180390021005]
37. Ramos-Casals M, Brito-Zerón P, Perez-DE-Lis M, Diaz-Lagares C, Bove A, Soto MJ, Jimenez I, Belenguer R, Siso 
A, Muxí A, Pons F. Clinical and prognostic significance of parotid scintigraphy in 405 patients with primary Sjogren’s 
syndrome. J Rheumatol. 2010 Mar;37(3):585-90. Epub 2010 Jan 15. [Medline: 20080906] [doi: 10.3899/jrheum.090835]
38. Güne SE, Yilmaz S, Karalezli A, Aktaş A. Quantitative and visual evaluation of salivary and thyroid glands in 
patients with primary Sjögren’s syndrome using salivary gland scintigraphy: relationship with clinicopathological 
features of salivary, lacrimal and thyroid glands. Nucl Med Commun. 2010 Jul;31(7):666-72 [Medline: 20545046] 
[doi: 10.1097/MNM.0b013e328339bdf6]
39. Kang J, Jang S, Lee W, Jang S, Lee Y, Kim S. Evaluation of salivary gland dysfunction using salivary gland scintigraphy 
in Sjögren’s syndrome patients and in thyroid cancer patients after radioactive iodine therapy. Nucl Med Mol Imaging. 
2011;45(3):161-8. [doi: 10.1007/s13139-011-0091-y]
http://www.ejomr.org/JOMR/archives/2012/1/e3/v3n1e3ht.htm J Oral Maxillofac Res 2012 (Jan-Mar) | vol. 3 | No 1 | e3 | p.12
(page number not for citation purposes)
JOURNAL OF ORAL & MAXILLOFACIAL RESEARCH                                                                  Gomes et al. 
40. Niemelä RK, Takalo R, Pääkkö E, Suramo I, Päivänsalo M, Salo T, Hakala M. Ultrasonography of salivary glands 
in primary Sjogren’s syndrome. A comparison with magnetic resonance imaging and magnetic resonance sialography 
of parotid glands. Rheumatology (Oxford). 2004 Jul;43(7):875-9. Epub 2004 Apr 27. [Medline: 15113992] 
[doi: 10.1093/rheumatology/keh187] [FREE Full Text]
41. van den Berg I, Pijpe J, Vissink A. Salivary gland parameters and clinical data related to the underlying 
disorder in patients with persisting xerostomia. Eur J Oral Sci. 2007 Apr;115(2):97-102. [Medline: 17451498] 
[doi: 10.1111/j.1600-0722.2007.00432.x]
42. Roberts C, Parker GJ, Rose CJ, Watson Y, O’Connor JP, Stivaros SM, Jackson A, Rushton VE. Glandular function in Sjögren 
syndrome: assessment with dynamic contrast-enhanced MR imaging and tracer kinetic modeling--initial experience. 
Radiology. 2008 Mar;246(3):845-53. Epub 2008 Jan 30. [Medline: 18235107] [doi: 10.1148/radiol.2463070298] 
[FREE Full Text]
43. Varghese JC, Thornton F, Lucey BC, Walsh M, Farrell MA, Lee MJ. A prospective comparative study of MR sialography 
and conventional sialography of salivary duct disease. AJR Am J Roentgenol. 1999 Dec;173(6):1497-503. [Medline: 
10584790] [FREE Full Text]
44. Ohbayashi N, Yamada I, Yoshino N, Sasaki T. Sjögren syndrome: comparison of assessments with MR sialography and 
conventional sialography. Radiology. 1998 Dec;209(3):683-8. [Medline: 9844659]
45. Morimoto Y, Habu M, Tomoyose T, Ono K, Tanaka T, Yoshioka I, Tominaga K, Yamashita Y, Ansai T, Kito S, 
Okabe S, Takahashi T, Takehara T, Fukuda J, Inenaga K, Ohba T. Dynamic magnetic resonance sialography as a new 
diagnostic technique for patients with Sjögren’s syndrome. Oral Dis. 2006 Jul;12(4):408-14. [Medline: 16792727] 
[doi: 10.1111/j.1601-0825.2005.01215.x]
46. Tanaka T, Ono K, Ansai T, Yoshioka I, Habu M, Tomoyose T, Yamashita Y, Nishida I, Oda M, Kuroiwa H, Wakasugi-
Sato N, Okabe S, Kito S, Takahashi T, Tominaga K, Inenaga K, Morimoto Y. Dynamic magnetic resonance sialography 
for patients with xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Jul;106(1):115-23. Epub 2008 
May 27. [Medline: 18504153] [doi: 10.1016/j.tripleo.2008.03.012]
47. Bialek EJ, Jakubowski W, Zajkowski P, Szopinski KT, Osmolski A. US of the major salivary glands: anatomy and 
spatial relationships, pathologic conditions, and pitfalls. Radiographics. 2006 May-Jun;26(3):745-63. Review. 
[Medline: 16702452] [doi: 10.1148/rg.263055024]
48. Wernicke D, Hess H, Gromnica-Ihle E, Krause A, Schmidt WA. Ultrasonography of salivary glands -- a highly specific 
imaging procedure for diagnosis of Sjögren’s syndrome. J Rheumatol. 2008 Feb;35(2):285-93. Epub 2008 Jan 15. 
[Medline: 18203316]
49. Milic V, Petrovic R, Boricic I, Radunovic G, Marinkovic-Eric J, Jeremic P, Damjanov N. Ultrasonography of major 
salivary glands could be an alternative tool to sialoscintigraphy in the American-European classification criteria 
for primary Sjogren’s syndrome. Rheumatology (Oxford). 2012 Feb 1. [Epub ahead of print] [Medline: 22302061] 
[doi: 10.1093/rheumatology/ker431].
50. Takagi Y, Kimura Y, Nakamura H, Sasaki M, Eguchi K, Nakamura T. Salivary gland ultrasonography: can it be an 
alternative to sialography as an imaging modality for Sjogren’s syndrome? Ann Rheum Dis. 2010 Jul;69(7):1321-4. 
Epub 2010 May 24. [Medline: 20498211] [doi: 10.1136/ard.2009.123836]
51. Ryu OH, Atkinson JC, Hoehn GT, Illei GG, Hart TC. Identification of parotid salivary biomarkers in Sjogren’s syndrome 
by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry and two-dimensional difference 
gel electrophoresis. Rheumatology (Oxford). 2006 Sep;45(9):1077-86. Epub 2006 Mar 7. [Medline: 16522680] 
[doi: 10.1093/rheumatology/kei212] [FREE Full Text]
52. Hu S, Wang J, Meijer J, Ieong S, Xie Y, Yu T, Zhou H, Henry S, Vissink A, Pijpe J, Kallenberg C, Elashoff D, Loo 
JA, Wong DT. Salivary proteomic and genomic biomarkers for primary Sjögren’s syndrome. Arthritis Rheum. 2007 
Nov;56(11):3588-600. [Medline: 17968930] [doi: 10.1002/art.22954] [FREE Full Text]
53. Fleissig Y, Deutsch O, Reichenberg E, Redlich M, Zaks B, Palmon A, Aframian DJ. Different proteomic protein patterns 
in saliva of Sjögren’s syndrome patients. Oral Dis. 2009 Jan;15(1):61-8. Epub 2008 Oct 9. [Medline: 18939961] 
[doi: 10.1111/j.1601-0825.2008.01465.x]
54. Ferraccioli G, De Santis M, Peluso G, Inzitari R, Fanali C, Bosello SL, Iavarone F, Castagnola M. Proteomic approaches 
to Sjögren’s syndrome: a clue to interpret the pathophysiology and organ involvement of the disease. Autoimmun Rev. 
2010 Jul;9(9):622-6. Epub 2010 May 10. Review. [Medline: 20462525] [doi: 10.1016/j.autrev.2010.05.010]
55. Castagnola M, Cabras T, Iavarone F, Fanali C, Nemolato S, Peluso G, Bosello SL, Faa G, Ferraccioli G, Messana I. 
The human salivary proteome: a critical overview of the results obtained by different proteomic platforms. Expert Rev 
Proteomics. 2012;9(1):33-46. [Medline: 22292822] [doi: 10.1586/epr.11.77]
56. Pedersen AM, Bardow A, Nauntofte B. Salivary changes and dental caries as potential oral markers of autoimmune 
salivary gland dysfunction in primary Sjogren’s syndrome. BMC Clin Pathol. 2005 Mar 1;5(1):4. [Medline: 15740617] 
[doi: 10.1186/1472-6890-5-4] [FREE Full Text]
http://www.ejomr.org/JOMR/archives/2012/1/e3/v3n1e3ht.htm J Oral Maxillofac Res 2012 (Jan-Mar) | vol. 3 | No 1 | e3 | p.13
(page number not for citation purposes)
JOURNAL OF ORAL & MAXILLOFACIAL RESEARCH                                                                  Gomes et al. 
57. Gannot G, Lancaster HE, Fox PC. Clinical course of primary Sjögren’s syndrome: salivary, oral, and serologic aspects. 
J Rheumatol. 2000 Aug;27(8):1905-9. [Medline: 10955331] 
58. Ramos-Casals M, Font J, Garcia-Carrasco M, Brito MP, Rosas J, Calvo-Alen J, Pallares L, Cervera R, Ingelmo M. 
Primary Sjögren syndrome: hematologic patterns of disease expression. Medicine (Baltimore). 2002 Jul;81(4):281-92. 
Review.. [Medline: 12169883] [doi: 10.1097/00005792-200207000-00004]
59. Ramos-Casals M, Font J. Primary Sjögren’s syndrome: current and emergent aetiopathogenic concepts. 
Rheumatology (Oxford). 2005 Nov;44(11):1354-67. Epub 2005 Jun 14. Review. [Medline: 15956090] 
[doi: 10.1093/rheumatology/keh714] [FREE Full Text]
60. Satoh M, Vázquez-Del Mercado M, Chan EK. Clinical interpretation of antinuclear antibody tests in systemic 
rheumatic diseases. Mod Rheumatol. 2009;19(3):219-28. Epub 2009 Mar 10. Review. [Medline: 19277826] 
[doi: 10.1007/s10165-009-0155-3] [FREE Full Text]
61. Huo AP, Lin KC, Chou CT. Predictive and prognostic value of antinuclear antibodies and rheumatoid 
factor in primary Sjogren’s syndrome. Int J Rheum Dis. 2010 Feb 1;13(1):39-47.. [Medline: 20374383] 
[doi: 10.1111/j.1756-185X.2009.01444.x]
62. Peen E, Mellbye OJ, Haga HJ. IgA rheumatoid factor in primary Sjogren’s syndrome. Scand J Rheumatol. 2009 Jan-
Feb;38(1):46-9. [Medline: 18942022] [doi: 10.1080/03009740802366043]
63. Franceschini F, Cavazzana I. Anti-Ro/SSA and La/SSB antibodies. Autoimmunity. 2005;38(1):55-63. 
[doi: 10.1080/08916930400022954]
64. Nakamura H, Kawakami A, Hayashi T, Iwamoto N, Okada A, Tamai M, Yamasaki S, Ida H, Eguchi K. Anti-centromere 
antibody-seropositive Sjögren’s syndrome differs from conventional subgroup in clinical and pathological study. BMC 
Musculoskelet Disord. 2010 Jul 1;11:140. [Medline: 20591195] [doi: 10.1186/1471-2474-11-140] [FREE Full Text]
65. Witte T, Matthias T, Arnett FC, Peter HH, Hartung K, Sachse C, Wigand R, Braner A, Kalden JR, Lakomek HJ, Schmidt 
RE. IgA and IgG autoantibodies against alpha-fodrin as markers for Sjögren’s syndrome. Systemic lupus erythematosus. 
J Rheumatol. 2000 Nov;27(11):2617-20. [Medline: 11093442]
66. Sumida T, Tsuboi H, Iizuka M, Nakamura Y, Matsumoto I. Functional role of M3 muscarinic acetylcholine receptor 
(M3R) reactive T cells and anti-M3R autoantibodies in patients with Sjögren’s syndrome. Autoimmun Rev. 2010 
Jul;9(9):615-7. Epub 2010 May 10. Review. [Medline: 20462524] [doi: 10.1016/j.autrev.2010.05.008]
67. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and 
predictive classification of primary Sjögren’s syndrome. Arthritis Rheum. 2002 Mar;46(3):741-7. [Medline: 11920410] 
[doi: 10.1002/art.10221]
68. Solans-Laqué R, López-Hernandez A, Bosch-Gil JA, Palacios A, Campillo M, Vilardell-Tarres M. Risk, predictors, 
and clinical characteristics of lymphoma development in primary Sjögren’s syndrome. Semin Arthritis Rheum. 2011 
Dec;41(3):415-23. Epub 2011 Jun 12. [Medline: 21665245] [doi: 10.1016/j.semarthrit.2011.04.006]
To cite this article:
Gomes PD, Juodzbalys G, Fernandes MH, Guobis Z. Diagnostic Approaches to Sjögren’s Syndrome: a Literature Review and 
Own Clinical Experience.
J Oral Maxillofac Res 2012;3(1):e3
URL: http://www.ejomr.org/JOMR/archives/2012/1/e3/v3n1e3ht.pdf
doi: 10.5037/jomr.2012.3103
Copyright © Gomes PD, Juodzbalys G, Fernandes MH, Guobis Z. Accepted for publication in the JOURNAL OF ORAL & 
MAXILLOFACIAL RESEARCH (http://www.ejomr.org), 20 March 2012
This is an open-access article, first published in the JOURNAL OF ORAL & MAXILLOFACIAL RESEARCH, distributed 
under the terms of the Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 Unported License, which 
permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work and is 
properly cited. The copyright, license information and link to the original publication on (http://www.ejomr.org) must be 
included.
